...
首页> 外文期刊>NMR in biomedicine >Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T-2-weighted and diffusion-weighted MRI
【24h】

Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T-2-weighted and diffusion-weighted MRI

机译:通过T-2加权和弥散加权MRI监测非霍奇金淋巴瘤异种移植物对化学疗法的反应

获取原文
获取原文并翻译 | 示例

摘要

An effective method for in vivo detection of early therapeutic response of patients with non-Hodgkin's lymphoma would enable personalized clinical management of cancer therapy and facilitate the design of optimal treatment regimens. This study evaluates the feasibility of T-weighted MRI (T2WI) and diffusion-weighted MRI (DWI) for in vivo detection of response of human diffuse large B-cell lymphoma xenografts in severe combined immunodeficient mice to chemotherapy. Each cycle of combination chemotherapy with cyclophosphamide, hydroxydoxorubicin, Oncovin, prednisone, and bryostatin 1 (CHOPB) was administered to tumor-carrying mice weekly for up to four cycles. T2WI and DWI were performed before the initiation of CHOPB and after each cycle of CHOPB. In order to corroborate the MRI results, histological analyses were carried out on control tumors and treated tumors after completion of all MRI studies. DWI revealed a significant (P < 0.03) increase in the mean apparent diffusion coefficient in CHOPB-treated tumors as early as 1 week after initiation of CHOPB. However, a significant (P < 0.03) decrease in mean T, was observed only after two cycles of CHOPB. Both MRI methods produced high-resolution (0.1 x 0.1 x 1.0 mm(3)) maps of regional therapeutic response in the treated tumors based on local apparent diffusion coefficient and T-2. Only a specific region of the tumors (in 3 of the 5 tumors) corresponding to about one third of the turner volume exhibited a response-associate increase in ADC and decrease in T,. An adjacent region exhibited an increase in T-2, and no change in ADC. The rest of the tumor was indistinguishable from sham-treated controls by MRI criteria. The therapeutic response of the treated tumors detected by MRI was accompanied by changes in tumor cell density, proliferation and apoptosis revealed by histological studies performed upon completion of the longitudinal study. The mechanism producing the regional response of the tumor remains to be elucidated. Copyright (c) 2008 John Wiley & Sons, Ltd.
机译:一种有效检测非霍奇金淋巴瘤患者早期治疗反应的有效方法,将有助于癌症治疗的个性化临床管理,并有助于设计最佳治疗方案。这项研究评估了T加权MRI(T2WI)和弥散加权MRI(DWI)在体内检测重度联合免疫缺陷小鼠对化学疗法的人弥漫性大B细胞淋巴瘤异种移植物反应的可行性。与环磷酰胺,羟基阿霉素,Oncovin,泼尼松和bryostatin 1(CHOPB)联合化疗的每个周期,每周一次向携带肿瘤的小鼠给药,最多四个周期。在CHOPB开始之前和每个CHOPB周期之后进行T2WI和DWI。为了证实MRI结果,在完成所有MRI研究后,对对照肿瘤和治疗的肿瘤进行组织学分析。 DWI揭示,早在CHOPB开始后1周,CHOPB治疗的肿瘤的平均表观扩散系数显着增加(P <0.03)。但是,仅在两个CHOPB循环后,才观察到平均T显着降低(P <0.03)。两种MRI方法均根据局部表观扩散系数和T-2产生了高分辨率(0.1 x 0.1 x 1.0 mm(3))的区域治疗反应图谱。仅对应于特纳体积的约三分之一的肿瘤的特定区域(在5个肿瘤中的3个中)显示出与响应相关的ADC增加和T 1的减少。相邻区域的T-2升高,而ADC不变。根据MRI标准,其余肿瘤与假手术对照组无区别。通过MRI检测到的治疗肿瘤的治疗反应伴随着在纵向研究完成后进行的组织学研究揭示的肿瘤细胞密度,增殖和凋亡的变化。产生肿瘤区域反应的机制尚待阐明。版权所有(c)2008 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号